Effectiveness of a Hospital-Based Work Support Intervention for Female Cancer Patients – A Multi-Centre Randomised Controlled Trial
Effectiveness of a Hospital-Based Work Support Intervention for Female Cancer Patients – A Multi-Centre Randomised Controlled Trial
![Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0137-3/MediaObjects/41523_2019_137_Fig4_HTML.png)
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer
![Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0137-3/MediaObjects/41523_2019_137_Fig2_HTML.png)
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer
![Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer | Journal of Clinical Oncology Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2021/jco.2021.39.issue-6/jco.20.03007/20210209/images/large/jco.20.03007t1.jpeg)
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer | Journal of Clinical Oncology
![Sanofi hit with charges of 'widespread' email deletion in legal saga stemming from Zantac recalls | FiercePharma Sanofi hit with charges of 'widespread' email deletion in legal saga stemming from Zantac recalls | FiercePharma](https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/fiercepharma/1620826715/Zantac%20800.png/Zantac%20800.png?VersionId=053WocilQm9UlgV1iotnb.PeE6h9s1aU&itok=3amsm0jA)
Sanofi hit with charges of 'widespread' email deletion in legal saga stemming from Zantac recalls | FiercePharma
![Indian Education Professional Development Program Archives - Office of Elementary and Secondary Education Indian Education Professional Development Program Archives - Office of Elementary and Secondary Education](https://i.ytimg.com/vi/KnQ88vPaP98/maxresdefault.jpg)
Indian Education Professional Development Program Archives - Office of Elementary and Secondary Education
![PDF) Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials PDF) Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials](https://i1.rgstatic.net/publication/49629892_Dose-Dense_Chemotherapy_in_Nonmetastatic_Breast_Cancer_A_Systematic_Review_and_Meta-analysis_of_Randomized_Controlled_Trials/links/09e4151100a7c37679000000/largepreview.png)
PDF) Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
![COVID-fighting antibodies last 4+ months in 87% of cancer patients: Israeli MDs | The Times of Israel COVID-fighting antibodies last 4+ months in 87% of cancer patients: Israeli MDs | The Times of Israel](https://static.timesofisrael.com/www/uploads/2021/08/F210804YS11.jpg)
COVID-fighting antibodies last 4+ months in 87% of cancer patients: Israeli MDs | The Times of Israel
![PDF) dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function PDF) dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function](https://i1.rgstatic.net/publication/320454487_dTCApFs_a_derivative_of_a_novel_human_hormone_peptide_induces_apoptosis_in_cancer_cells_through_a_mechanism_involving_loss_of_Golgi_function/links/5a1d6eab4585153731899467/largepreview.png)
PDF) dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function
![Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0137-3/MediaObjects/41523_2019_137_Fig3_HTML.png)
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer
![Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-017-0033-7/MediaObjects/41523_2017_33_Fig1_HTML.jpg)
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer
![Trajectories of Injectable Cancer Drug Costs After Launch in the United States | Journal of Clinical Oncology Trajectories of Injectable Cancer Drug Costs After Launch in the United States | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2018/jco.2018.36.issue-4/jco.2016.72.2124/20180117/images/large/jco.2016.72.2124t1.jpeg)